TROP-2 expression in papillary thyroid cancer: a preliminary cyto-histological study
TROP-2 expression in papillary thyroid cancer: a preliminary cyto-histological study
复制标题
DOI：
10.1111/cyt.12196
复制
发表时间：
2015-10-01
期刊：
影响因子：
1.3
通讯作者：
Simone, G.
中科院分区：
文献类型：
--
作者：
Addati, T.;Achille, G.;Simone, G.
目的：TR 0 P-2（人滋养层细胞表面标志物）是在滋养层细胞中表达的基因相关蛋白，其也存在于多种上皮癌中，并且已发现其过表达与不良预后相关。我们分析了TROP-2在细胞学和组织学标本中检测甲状腺乳头状癌（PTC）的可能性，并与Hector Battifora mesothelialantigen-1（HBME-1）进行了比较。从127例患者中，127例细针抽吸物（FNAs）中，免疫细胞化学（ICC）检测HBME-1，根据Bethesda甲状腺细胞病理学报告系统（TBSRTC）重新分类：20%为良性，56%为意义不明的非典型细胞/滤泡病变（AUS/ FLUS），4%为滤泡性肿瘤/疑似滤泡性肿瘤，5%疑似恶性肿瘤，16%为恶性肿瘤。在64个FNA中可获得足够的材料来测试TROP-2，其中22个具有组织学对照。包括另外6例FNAs不可用的病例，对94例病例进行了两种标记物的免疫组织化学（IHC）。在88例有组织学对照的FNA中，HBME-1预测PTC的敏感性为87.5%（28/32），特异性为86%（48/56），而在22例FNA中，TROP-2诊断乳腺癌的敏感性为100%（13/13），特异性为8/9%（8/9）。在94例组织学标本中，用两种标记物进行IHC，HBME-1的灵敏度和特异性分别为82%和86%，TROP-2的灵敏度和特异性分别为87%和89%。标记物之间的差异不显著。HBME-1与ICC的符合率分别为76%和91%。结论：TROP-2可与HBME-1一样用于甲状腺细胞学检查。两种标志物中的一种或两种阳性有助于对不确定的FNA进行恶性风险分层。需要更大规模的研究来分析其在PTC及其变体行为中的作用。
Objective: TROP-2 (human trophoblast cell surface marker) is a gene-related protein expressed in trophoblastic cells, which is also present in a variety of epithelial cancers and whose overexpression has been found to correlate with a poor prognosis. We analysed the possibility of using the expression of TROP-2 to detect papillary thyroid carcinoma (PTC) on cytological and histological samples, and compared it with Hector Battifora mesothelial antigen-1 (HBME-1).Methods: From 127 patients, 127 fine needle aspirates (FNAs), in which HBME-1 was detected by immunocytochemistry (ICC), were re-classified according to the Bethesda system for reporting thyroid cytopathology (TBSRTC): 20% were benign, 56% were atypical cells/follicular lesion of undetermined significance (AUS/ FLUS), 4% were follicular neoplasm/suspicious for a follicular neoplasm, 5% were suspicious for malignancy and 16% were malignant. Sufficient material to test for TROP-2 was available in 64 FNAs, 22 of which had a histological control. Including six additional cases in which the FNAs were not available, immunohistochemistry (IHC) was carried out with both markers on 94 cases.Results: Among 88 FNAs with histological control, the sensitivity of HBME-1 to predict PTC was 87.5% (28/32) and the specificity was 86% (48/56), whereas, in 22 FNAs, TROP-2 sensitivity was 100% (13/13) and specificity was 89% (8/9). In 94 histological specimens in which IHC was carried out with both markers, the sensitivity and specificity were 82% and 86%, respectively, for HBME-1 and 87% and 89%, respectively, for TROP-2. The difference between the markers was not significant. Concordance between IHC and ICC was 76% for HBME-1 and 91% for TROP-2.Conclusion: TROP-2 can be used as well as HBME-1 in thyroid cytology to detect PTC. Positivity for either or both markers could help to stratify the risk of malignancy in indeterminate FNAs. Larger studies are need to analyse its role in the behaviour of PTC and its variants.